Document is current
Any future updates will be listed below
-
Authors
Michonneau, David https://orcid.org/0000-0003-4553-3065
Malard, Florent
Le Grand, Sophie https://orcid.org/0000-0002-9985-465X
Magro, Leonardo
D’Aveni, Maud https://orcid.org/0000-0002-5909-2742
Tudesq, Jean Jacques https://orcid.org/0000-0003-4879-8106
Villate, Alban
Meunier, Mathieu
Maillard, Natacha
Castilla-Llorente, Cristina
Marçais, Ambroise https://orcid.org/0000-0002-6844-7920
Cabrera, Quentin
Huynh, Anne
Menard, Anne-Lise
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Labussière-Wallet, Hélène
Raus, Nicole
Loschi, Michael https://orcid.org/0000-0002-4460-5939
- License Information
-
More Information
Article History
Received: 27 January 2025
Revised: 11 February 2025
Accepted: 12 March 2025
First Online: 1 April 2025
Competing interests
: DM received research grants from Novartis, Sanofi and CSL Behring, consulting fees from Novartis, Incyte, Sanofi, Jazz Pharmaceuticals, and Mallinckrodt. FM received honoraria from Therakos/Mallinckrodt, Janssen, Biocodex, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, Priothera, and Astellas. EF received speaker fees and honoraria for advisory board from Novartis, Sanofi, Gilead, Alexion, MSD, Astellas, Jazz, Pfizer, GSK and Sobi. ML received research grant from Janssen, consulting honoraria from Abbvie, Alexion, Bristol Myers Squibb, Gilead, Glaxo Smith Kline, Incyte, Jazz, Kartos, Mallinkrodt, Novartis, Roche, Sanofi, Takeda. Other authors did not declare any competing interests.
